SQLE is called squalene epoxidase, which acts as an oncogenic role in tumors, including breast cancer.[43, 44] Ectopic expression of SQLE drives NAFLD‐induced hepatocellular carcinoma and becomes a potential pharmacological target.[45] In breast cancer, CASIMO1 has been reported to interact with SQLE impacting the cell's metabolic homeostasis.[46] In small cell lung cancer, SQLE binds to microRNAs and affects downstream target gene expression.[47] However, the function of SQLE on CSCs has not been elucidated. The gene discussed is SMIM22; the disease is metabolic dysfunction-associated steatotic liver disease.